Aminologics Co.,Ltd. (KOSDAQ:074430)
South Korea · Delayed Price · Currency is KRW 1,519.00
-6.00 (-0.39%)
At close: Feb 27, 2026
Aminologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Other Revenue | 0 | - | - | -0 | -0 | - |
| 19,516 | 16,790 | 20,887 | 27,337 | 22,849 | 17,651 | |
Revenue Growth (YoY) | -6.56% | -19.61% | -23.60% | 19.64% | 29.45% | -7.00% |
Cost of Revenue | 11,910 | 13,406 | 13,153 | 14,547 | 13,721 | 10,676 |
Gross Profit | 7,606 | 3,384 | 7,734 | 12,790 | 9,128 | 6,975 |
Selling, General & Admin | 5,220 | 4,966 | 4,527 | 5,179 | 4,255 | 3,912 |
Research & Development | 155.14 | 112.54 | 1,307 | 215.51 | 474.13 | 339.66 |
Amortization of Goodwill & Intangibles | 18.83 | 19.64 | 19.7 | 19.26 | 16.31 | 12.31 |
Other Operating Expenses | -2.61 | -6.05 | -8.14 | 9.56 | 16.06 | 19.89 |
Operating Expenses | 5,868 | 5,537 | 6,272 | 5,881 | 5,174 | 4,391 |
Operating Income | 1,739 | -2,153 | 1,462 | 6,908 | 3,953 | 2,584 |
Interest Expense | -760.76 | -83.42 | -57.08 | -40.01 | -30.92 | -36.32 |
Interest & Investment Income | 1,209 | 1,175 | 929.76 | 525.7 | 198.06 | 254.86 |
Currency Exchange Gain (Loss) | 522.98 | 879.8 | -75.28 | 397.24 | 465.53 | -359.73 |
Other Non Operating Income (Expenses) | 806.99 | 42.61 | 133.25 | 105.51 | -8.26 | 328.19 |
EBT Excluding Unusual Items | 3,517 | -138.97 | 2,393 | 7,897 | 4,578 | 2,771 |
Gain (Loss) on Sale of Investments | -219.12 | 11.98 | -101.82 | -659.69 | 658.99 | -696.82 |
Gain (Loss) on Sale of Assets | - | 8.41 | - | - | - | - |
Asset Writedown | -986 | -986 | - | -13,518 | -1,533 | - |
Pretax Income | 2,312 | -1,105 | 2,291 | -6,281 | 3,704 | 2,074 |
Income Tax Expense | 359.92 | 515.44 | -145.31 | 1,001 | -1,656 | -66 |
Net Income | 1,952 | -1,620 | 2,436 | -7,282 | 5,360 | 2,140 |
Net Income to Common | 1,952 | -1,620 | 2,436 | -7,282 | 5,360 | 2,140 |
Net Income Growth | 5.11% | - | - | - | 150.46% | - |
Shares Outstanding (Basic) | 76 | 88 | 88 | 88 | 88 | 88 |
Shares Outstanding (Diluted) | 76 | 88 | 88 | 88 | 88 | 88 |
Shares Change (YoY) | -23.92% | - | - | - | - | - |
EPS (Basic) | 25.72 | -18.45 | 27.74 | -82.91 | 61.03 | 24.37 |
EPS (Diluted) | 25.72 | -18.45 | 27.74 | -82.91 | 61.03 | 24.37 |
EPS Growth | 38.15% | - | - | - | 150.46% | - |
Free Cash Flow | 1,254 | 6,955 | -373.95 | 4,736 | 419.81 | 1,460 |
Free Cash Flow Per Share | 16.52 | 79.19 | -4.26 | 53.92 | 4.78 | 16.62 |
Gross Margin | 38.97% | 20.16% | 37.03% | 46.79% | 39.95% | 39.52% |
Operating Margin | 8.91% | -12.82% | 7.00% | 25.27% | 17.30% | 14.64% |
Profit Margin | 10.00% | -9.65% | 11.66% | -26.64% | 23.46% | 12.12% |
Free Cash Flow Margin | 6.42% | 41.42% | -1.79% | 17.32% | 1.84% | 8.27% |
EBITDA | 2,234 | -1,688 | 1,908 | 7,259 | 4,232 | 2,811 |
EBITDA Margin | 11.45% | -10.05% | 9.14% | 26.55% | 18.52% | 15.92% |
D&A For EBITDA | 495.48 | 465.43 | 446.15 | 350.84 | 278.81 | 226.97 |
EBIT | 1,739 | -2,153 | 1,462 | 6,908 | 3,953 | 2,584 |
EBIT Margin | 8.91% | -12.82% | 7.00% | 25.27% | 17.30% | 14.64% |
Advertising Expenses | - | 132.5 | 91.26 | 26.12 | 63.09 | 45.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.